Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$86.53 USD
+0.55 (0.64%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $86.49 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
AXSM 86.53 +0.55(0.64%)
Will AXSM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AXSM
Alkermes' (ALKS) Q2 Earnings Miss Estimates, Revenues Beat
Wall Street Analysts Predict a 49.36% Upside in Axsome (AXSM): Here's What You Should Know
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
Acadia's (ACAD) Nuplazid Drives Growth, Pipeline Setbacks a Woe
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
Other News for AXSM
Cantor Fitzgerald Remains a Buy on Axsome Therapeutics (AXSM)
Axsome Therapeutics: Lots Of Moving Parts
7 Biotech Stocks to Keep on Your Clinical Radar
RBC Capital Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Axsome Therapeutics initiated with bullish view at Needham, here's why